Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Share-based Compensation (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Share-based Compensation for 3 consecutive years, with $3.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation rose 7.08% to $3.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $11.4 million, a 81.64% decrease, with the full-year FY2024 number at $58.5 million, up 135.52% from a year prior.
  • Share-based Compensation was $3.2 million for Q3 2025 at Inhibrx Biosciences, up from $2.8 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $46.2 million in Q2 2024 to a low of $2.4 million in Q1 2025.
  • A 3-year average of $8.9 million and a median of $3.2 million in 2025 define the central range for Share-based Compensation.
  • Biggest YoY gain for Share-based Compensation was 7.08% in 2025; the steepest drop was 94.0% in 2025.
  • Inhibrx Biosciences' Share-based Compensation stood at $6.4 million in 2023, then crashed by 53.6% to $3.0 million in 2024, then grew by 6.47% to $3.2 million in 2025.
  • Per Business Quant, the three most recent readings for INBX's Share-based Compensation are $3.2 million (Q3 2025), $2.8 million (Q2 2025), and $2.4 million (Q1 2025).